A comparison of drug binding sites on mammalian albumins.
The fluorescent probes warfarin and dansylsarcosine are known to selectively interact with binding sites I and II, respectively, on human albumin. This paper investigates whether similar binding sites exist on bovine, dog, horse, sheep and rat albumins. Binding sites on albumins were studied by: (1) displacement of warfarin and dansylsarcosine by site I (phenylbutazone) and site II (diazepam) selective ligands; (2) the effects of non-esterified fatty acids (carbon chain lengths: C5-C20) and changes in pH (6-9) on the fluorescence of warfarin and dansylsarcosine; and (3) the ability of site selective ligands to inhibit hydrolysis of 4-nitrophenyl acetate. For bovine, dog, horse, human and sheep albumins the fluorescence of bound warfarin and dansylsarcosine was selectively decreased by phenylbutazone and diazepam, respectively. For these albumins medium chain fatty acids (C1-C12) reduced the fluorescence of dansylsarcosine (maximum inhibition with C9) whereas long chain acids (C12-C20) enhanced the fluorescence of warfarin (maximum increases with C12). In addition, changes in pH from 6 to 9 increased the fluorescence of warfarin and although site I ligands (warfarin/phenylbutazone) had no pronounced effects on 4-nitrophenyl acetate hydrolysis, site II ligands (dansylsarcosine/diazepam) significantly inhibited this reaction. Rat albumin behaved differently from the other albumins studied in that the C12-C20 fatty acids and changes in pH did not enhance the fluorescence of warfarin. Moreover, the differential effects of site I and site II ligands on the fluorescence of warfarin/dansylsarcosine and hydrolysis of 4-nitrophenyl acetate were less apparent with rat albumin. The results suggest bovine, dog, horse and sheep albumins have binding sites for warfarin and dansylsarcosine with similar properties to sites I and II on human albumin. By contrast, the warfarin binding site and to a lesser degree the dansylsarcosine site, of rat albumin have different characteristics from these sites on the other albumins studied.
Panjehshahin
M R
MR
Department of Pharmacology, University of Leeds, U.K.
Yates
M S
MS
Bowmer
C J
CJ
D000418:Albumins / Q000737:chemistry*; D000818:Animals; D001665:Binding Sites; D001667:Binding, Competitive; D002417:Cattle; D003619:Dansyl Compounds / Q000737:chemistry; D003975:Diazepam / Q000737:chemistry / Q000494:pharmacology; D004285:Dogs; D005230:Fatty Acids, Nonesterified / Q000494:pharmacology; D005453:Fluorescence; D006736:Horses; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007700:Kinetics; D009596:Nitrophenols / Q000737:chemistry; D010653:Phenylbutazone / Q000737:chemistry / Q000494:pharmacology; D051381:Rats; D012521:Sarcosine / Q000031:analogs & derivatives / Q000737:chemistry; D012756:Sheep; D014859:Warfarin / Q000737:chemistry
D000418:Albumins; D003619:Dansyl Compounds; D005230:Fatty Acids, Nonesterified; D009596:Nitrophenols; C037087:dansylsarcosine; D014859:Warfarin; C008642:4-nitrophenyl acetate; D010653:Phenylbutazone; D003975:Diazepam; D012521:Sarcosine